<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03799822</url>
  </required_header>
  <id_info>
    <org_study_id>OLV 2014/065</org_study_id>
    <nct_id>NCT03799822</nct_id>
  </id_info>
  <brief_title>Effect on Calcification of Replacing Warfarin by Rivaroxaban With or Without Vit K2 Supplements in HD; Extension Study</brief_title>
  <official_title>The Effect of Replacement of Vitamin K Antagonist by Rivaroxaban With or Without Vitamin K2 Supplementation on Vascular Calcifications in Chronic Hemodialysis Patients: a Randomized Controlled Trial, Extension Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Onze Lieve Vrouw Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Onze Lieve Vrouw Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators refer to the trial with clinicaltrials.gov indentifier NCT02610933 entitled
      Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2
      in Hemodialysis Patients.

      After termination of this trial, included patients will be asked to participate in the
      extension trial by continuing the treament of their respective allocation arm. No new
      intervention will be done.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators refer to the trial with clinicaltrials.gov indentifier NCT02610933 entitled
      Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2
      in Hemodialysis Patients.

      After termination of this trial, included patients will be asked to participate in the
      extension trial by continuing the treament of their respective allocation arm. No new
      intervention will be done. Relevant endpoints like death, cardiovascular events and bleeding
      episodes will be registered.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bleeding incidence</measure>
    <time_frame>through study completion, on average 3 years</time_frame>
    <description>minor or major bleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>death rate</measure>
    <time_frame>through study completion, on average 3 years</time_frame>
    <description>cause of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of cardiovascular events</measure>
    <time_frame>through study completion, on average 3 years</time_frame>
    <description>type of cardiovascular event</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Vascular Calcification</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hemodialysis patients with non valvular atrial fibrillation receiving warfarin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemodialysis patients with non valvular atrial fibrillation receiving rivaroxaban 10 mg od</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rivaroxaban + K2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemodialysis patients with non valvular atrial fibrillation receiving rivaroxaban 10 mg od + vitamin K2 supplements</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 10 MG Oral Tablet</intervention_name>
    <description>replacement of warfarin by rivaroxaban</description>
    <arm_group_label>rivaroxaban</arm_group_label>
    <arm_group_label>rivaroxaban + K2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MK-7 2000µg thrice weekly</intervention_name>
    <description>dietary supplement of vitamin K2 MK-7 2000µg thrice weekly</description>
    <arm_group_label>rivaroxaban + K2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin K Antagonist - Drug</intervention_name>
    <description>treatment with a vitamin K antagonist</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  inclusion in the trial with clinicaltrials.gov identifier NCT02610933

          -  signed informed consent for this extension trial

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rogier Caluwe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OLV Hospital Aalst, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OLV Hospital</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 7, 2019</study_first_submitted>
  <study_first_submitted_qc>January 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2019</study_first_posted>
  <last_update_submitted>January 11, 2019</last_update_submitted>
  <last_update_submitted_qc>January 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Onze Lieve Vrouw Hospital</investigator_affiliation>
    <investigator_full_name>Rogier Caluwe</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>rivaroxaban</keyword>
  <keyword>vitamin K2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcinosis</mesh_term>
    <mesh_term>Vascular Calcification</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

